The first consecutive 75 patients encountered with asymptomatic infrarenal AAA and 75 controls without AAA presenting to ambulatory clinics at St. Michaels Hospital (Toronto, Canada) between May 2017 ...

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...

Complement activation is usually controlled by regulatory factors such as complement factor H (CFH) and alteration of this process causes severe diseases such as atypical haemolytic uraemic syndrome ...